Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 9:58 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 1,551 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Ulcerative Clear all

Conditions: Upper Gastrointestinal Bleeding
Interventions: Clinician notification, Clinician Notification with Nurse Facilitation, Clinician Notification / Patient Activation, Clinician Notification with Nurse Facilitation / Patient Activation; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Congenital Heart Disease, Upper Gastrointestinal Bleeding, Stress Ulcer, Infection
Interventions: Famotidine, Placebo; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 1 Minute to 12 Months
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pyoderma Gangrenosum, Skin Diseases, Wound Heal, Pyoderma, Skin Ulcer
Interventions: Guselkumab; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Columbus, Ohio • Portland, Oregon

Conditions: Inflammatory Bowel Diseases
Interventions: ECG recording, inflammatory cytokines, microbiota, ulcerative colitis disease activity index; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Diabetic Foot Ulcers
Interventions: Nexagon® Low Dose, Nexagon® Medium Dose, Nexagon® High Dose, Nexagon® vehicle; Drug
Lead sponsor: OcuNexus Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 9
States / cities: Phoenix, Arizona • Tucson, Arizona • Castro Valley, California + 6 more

Conditions: Diabetic Foot Ulcer
Interventions: Podimetrics SmartMat; Device
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Venous Stasis Ulcers
Interventions: DermaStream; Device
Lead sponsor: EnzySurge; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Esophagitis, Reflux, Esophagitis, Peptic
Interventions: Dexlansoprazole MR, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 451 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 100
States / cities: Anniston, Alabama • Hueytown, Alabama • Huntsville, Alabama + 97 more

Conditions: Colitis, Ulcerative, Crohn's Disease
Interventions: Vedolizumab; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 7
States / cities: Aurora, Colorado • Chicago, Illinois • Urbana, Illinois + 4 more

Conditions: Pressure Ulcer, Ankle, Prosthesis User, Prosthesis Durability, Mobility Limitation, Skin Wound, Amputation; Traumatic, Foot, Amputation, Limb Deficiencies
Interventions: PROPRIO FOOT® by Ossur & Empower ankle by Ottobock; Device
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Pyoderma Gangrenosum
Interventions: Xilonix; Biological
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Tallahassee, Florida

Conditions: Venous Stasis Ulcer
Interventions: Erchonia ML Scanner (MLS), Placebo Laser; Device
Lead sponsor: Erchonia Corporation; Industry
Eligibility: 40 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Keratitis Bacterial
Interventions: Moxifloxacin Ophthalmic, Difluprednate Ophthalmic, Riboflavin Ophthalmic, Topical Placebo; Drug · Other
Lead sponsor: Thomas M. Lietman; Other
Eligibility: 18 Years and older
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 2
States / cities: San Francisco, California • Miami, Florida

Conditions: Venous Leg Ulcer
Interventions: TTAX01, Profore Compression Therapy, Cadexomer Iodine dressing; Biological · Other
Lead sponsor: BioTissue Holdings, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 6
States / cities: Carlsbad, California • Sylmar, California • North Chicago, Illinois + 3 more

Conditions: Ulcerative Colitis, Crohn's Disease
Interventions: Vedolizumab IV, Vedolizumab SC; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 101
States / cities: Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 89 more

Conditions: Wound, Pressure Injury
Interventions: Standardized nursing care; Other
Lead sponsor: Regional Medical Center of San Jose; Other
Eligibility: 18 Years and older
Enrollment: 352 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: San Jose, California

Conditions: Diabetic Foot Ulcer
Interventions: AutoloGel, Usual and Customary Care; Device · Other
Lead sponsor: Cytomedix; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Hattiesburg, Mississippi

Conditions: Inflammatory Bowel Disease (IBD), Crohn's Disease (CD), Ulcerative Colitis (UC)
Interventions: Inflectra; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 11
States / cities: San Diego, California • Hamden, Connecticut • Miami, Florida + 8 more

Conditions: Inflammatory Bowel Disease
Interventions: Not listed
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Ulcerative Colitis
Interventions: tofacitinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 19
States / cities: Los Angeles, California • San Francisco, California • Farmington, Connecticut + 10 more

Conditions: Diabetic Foot Ulcer
Interventions: Kerecis Omega3 Wound, Fibracol; Device
Lead sponsor: Kerecis Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 5
States / cities: Coconut Creek, Florida • Smyrna, Georgia • Carmel, Indiana + 2 more

Conditions: Ulcerative Colitis (UC)
Interventions: Ulcerative Colitis Diet, Antibiotic cocktail; Other · Drug
Lead sponsor: Prof. Arie Levine; Government
Eligibility: 8 Years to 19 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: IBD (Inflammatory Bowel Disease)
Interventions: Diet Management, Stress Management; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Crohn's Disease, Ulcerative Colitis, Inflammatory Bowel Disease
Interventions: Vedolizumab; Drug
Lead sponsor: Shaare Zedek Medical Center; Other
Eligibility: Up to 18 Years
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 4
States / cities: Hartford, Connecticut • Morristown, New Jersey • New York, New York + 1 more

Search by objective public record fields.

Anticoagulation With Enhanced Gastrointestinal Safety (AEGIS) Trial

Stress Ulcer Prophylaxis Versus Placebo in Critically Ill Infants With Congenital Heart Disease

Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG)

Autonomic and Cytokines Profiles of Patients With Ulcerative Proctitis

A Study to Investigate the Safety and Clinical Effect of Nexagon® as a Topical Treatment for Subjects With a Diabetic Foot Ulcer (DUNE)

Improving DFU Outcomes: Early Detection of Foot Ulcers Using Novel Technology

A Post Marketing Clinical Study Utilizing DermaStream and Saline in Venous Ulcers

Comparison of Dexlansoprazole MR to Placebo on the Ability to Maintain Healing in Subjects With Healed Erosive Esophagitis

Postmarketing Vedolizumab Milk-Only Lactation Study in Lactating Women With Active Ulcerative Colitis or Crohn's Disease

Limb Health and Socket Pressure in Response to Powered Ankle Protheses

A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum

Efficacy Study of the Application of Low Level Laser Light to Treat Venous Stasis Ulcers

Steroids and Cross-linking for Ulcer Treatment

Subjects With Non-Healing Venous Leg Ulcers Treated With Standard Care Plus Cryopreserved Human Umbilical Cord (TTAX01)

A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting

Wound Care and Pressure Injury Through the Continuum of Care

Efficacy of AutoloGel Therapy to Usual and Customary Care in Wagner gd 1 and 2 Diabetic Foot Ulcers.

Observational, Real World Study Of Inflectra In Patients With Inflammatory Bowel Disease

IBD-OPERA Database, UC Protocol

Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis

Omega3 Wound Fish Skin Graft in the Treatment of DFUs

Use of a Novel Diet (UC DIET) for Treatment of Mild to Moderate Active Pediatric Ulcerative Colitis

Diet and Stress Management Combined With Advanced Therapy for Crohn's and Ulcerative Colitis

Predicting Response to Vedolizumab in Pediatric Inflammatory Bowel Diseases